Literature DB >> 24412064

RIG-I modulates Src-mediated AKT activation to restrain leukemic stemness.

Xian-Yang Li1, Lin-Jia Jiang1, Lei Chen1, Meng-Lei Ding1, He-Zhou Guo1, Wu Zhang1, Hong-Xin Zhang2, Xiao-Dan Ma3, Xiang-Zhen Liu3, Xiao-Dong Xi3, Sai-Juan Chen3, Zhu Chen3, Jiang Zhu4.   

Abstract

Retinoic acid (RA)-inducible gene I (RIG-I) is highly upregulated and functionally implicated in the RA-induced maturation of acute myeloid leukemia (AML) blasts. However, the underlying mechanism and the biological relevance of RIG-I expression to the maintenance of leukemogenic potential are poorly understood. Here, we show that RIG-I, without priming by foreign RNA, inhibits the Src-facilitated activation of AKT-mTOR in AML cells. Moreover, in a group of primary human AML blasts, RIG-I reduction renders the Src family kinases hyperactive in promoting AKT activation. Mechanistically, a PxxP motif in RIG-I, upon the N-terminal CARDs' association with the Src SH1 domain, competes with the AKT PxxP motif for recognizing the Src SH3 domain. In accordance, mutating PxxP motif prevents Rig-I from inhibiting AKT activation, cytokine-stimulated myeloid progenitor proliferation, and in vivo repopulating capacity of leukemia cells. Collectively, our data suggest an antileukemia activity of RIG-I via competitively inhibiting Src/AKT association.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24412064     DOI: 10.1016/j.molcel.2013.12.008

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  22 in total

Review 1.  Clinical and Biological Implications of Cancer Stem Cells in Hepatocellular Carcinoma.

Authors:  Hiroyuki Tsuchiya; Goshi Shiota
Journal:  Yonago Acta Med       Date:  2021-01-06       Impact factor: 1.641

2.  Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signalling.

Authors:  Banu Iskender; Kenan Izgi; Esra Hizar; Johann Jauch; Aslihan Arslanhan; Esra Hilal Yuksek; Halit Canatan
Journal:  Tumour Biol       Date:  2015-12-30

3.  Retinoic acid inducible gene-I slows down cellular senescence through negatively regulating the integrin β3/p38 MAPK pathway.

Authors:  Junmei Zhao; Xinyi Jiang; Li Yan; Jian Lin; Hezhou Guo; Shanhe Yu; Baixin Ye; Jiang Zhu; Wu Zhang
Journal:  Cell Cycle       Date:  2019-10-09       Impact factor: 4.534

4.  Krüppel-like Factor 4 Supports the Expansion of Leukemia Stem Cells in MLL-AF9-driven Acute Myeloid Leukemia.

Authors:  Andrew Henry Lewis; Cory Seth Bridges; David Neal Moorshead; Taylor J Chen; Wa Du; Barry Zorman; Pavel Sumazin; Monica Puppi; H Daniel Lacorazza
Journal:  Stem Cells       Date:  2022-08-25       Impact factor: 5.845

5.  Functional role of autophagy-mediated proteome remodeling in cell survival signaling and innate immunity.

Authors:  Robin Mathew; Sinan Khor; Sean R Hackett; Joshua D Rabinowitz; David H Perlman; Eileen White
Journal:  Mol Cell       Date:  2014-08-28       Impact factor: 17.970

6.  RIG-I regulates myeloid differentiation by promoting TRIM25-mediated ISGylation.

Authors:  Song-Fang Wu; Li Xia; Xiao-Dong Shi; Yu-Jun Dai; Wei-Na Zhang; Jun-Mei Zhao; Wu Zhang; Xiang-Qin Weng; Jing Lu; Huang-Ying Le; Sheng-Ce Tao; Jiang Zhu; Zhu Chen; Yue-Ying Wang; Saijuan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-08       Impact factor: 11.205

Review 7.  mRNA cap regulation in mammalian cell function and fate.

Authors:  Alison Galloway; Victoria H Cowling
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2018-10-09       Impact factor: 4.490

8.  Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells.

Authors:  Bin Chen; Xin Xu; Jie Luo; Heyong Wang; Songwen Zhou
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

9.  CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.

Authors:  Xian-Yang Li; Indrajit Das; Ailin Lepletier; Venkateswar Addala; Tobias Bald; Kimberley Stannard; Deborah Barkauskas; Jing Liu; Amelia Roman Aguilera; Kazuyoshi Takeda; Matthias Braun; Kyohei Nakamura; Sebastien Jacquelin; Steven W Lane; Michele Wl Teng; William C Dougall; Mark J Smyth
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

10.  SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway.

Authors:  Kunkun Han; Xin Xu; Zhuan Xu; Guodong Chen; Yuanying Zeng; Zubin Zhang; Biyin Cao; Yan Kong; Xiaowen Tang; Xinliang Mao
Journal:  Sci Rep       Date:  2015-09-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.